(WASHINGTON, D.C.) – Pharmaceutical Care Management Association (PCMA) President and CEO, David Marin, issued the following statement on today’s markup in the Senate Committee on Health, Education, Labor, and Pensions (HELP), which includes consideration of S. 2355, Patients Deserve Price Tags Act and S. 4189, the INSULIN Act of 2026.

“Congress achieved a major victory this year by enshrining unprecedented PBM transparency into federal law. The priority now should be to advance legislation that ends drug manufacturer patent abuse and brings transparency to the rest of the drug supply chain. Instead, the Committee is advancing more, duplicative PBM reporting requirements that do nothing to help patients or employers.

“Transparency is critical, and PBMs are already required by law to provide it. The Patients Deserve Price Tags Act includes many of the same transparency targets Congress already enacted, just reported another way. This is the height of needless regulation that helps no one, makes care more expensive, and threatens competition in the PBM marketplace. We urge the committee to harmonize any new transparency policy with what it has already written into law.

“The INSULIN Act of 2026 reflects a commitment by the committee to help people struggling with diabetes. This is a conviction that PBMs share, having already capped insulin prices for the patients they serve. Today, the average copay for insulin in the commercial market is less than $15. In addition, Medicare recently implemented a $35 copay cap for seniors. What is missing from this legislation is any contribution from drug manufacturers to solve this affordability challenge. Any bill that only caps out-of-pocket costs gives drugmakers an incentive to raise insulin prices with impunity. Any serious effort to reduce costs must address list prices, not just regulate out-of-pocket expenses that will only give Big Pharma a blank check that will make pharmacy benefits more expensive for everyone.”